DYNAMICS OF BIOIMPEDANCE EXAMINATION INDICATORS OF OVERWEIGHT/OBESE PATIENTS IN COMBINATION WITH INSULIN RESISTANCE AGAINST THE BACKGROUND OF COMPLEX TREATMENT USING VITAGEN No. 29 METABOLISM PLUS
DOI:
https://doi.org/10.11603/1811-2471.2025.v.i1.15098Keywords:
overweight, obesity, insulin resistance, bioimpedance measurement, nutraceutical, treatmentAbstract
SUMMARY. The article describes and analyzes the dynamics of bioimpedasmetry indicators in patients with overweight/obesity and insulin resistance against the background of therapy using a multicomponent nutraceutical.
The aim – to evaluate changes in indicators of body composition in patients with overweight/obesity and insulin-resistance against the background of complex therapy with the additional use of a nutraceutical containing extract of Gymnema, Mamordica, 7-keto-dehydroepiandrosterone, L-tyrosine, Choline, Inositol and microelements.
Materials and Methods. 90 patients with overweight/obesity and IR who were examined by a gastroenterologist-nutritionist during 2024 were studied.
Results. It was established that complex therapy using a nutraceutical containing Gymnema extract, Momordica charantia, 7-keto-dehydroepiandrosterone, L-tyrosine, Choline, Inositol, and microelements has a positive effect on indicators of body composition and correction of insulin resistance in such patients. Their lipolytic effect, positive effect on metabolism, carbohydrate metabolism and modulation of indicators of the component composition of the body have been established. Namely, a month after the treatment, a decrease in the НOMA index was noted in all studied groups (to 5.23±1.24 in the group I, 3.53±1.04 in the group II, and 3.22±0.92 in the group III).
After comprehensive treatment of patients of all studied groups for a month, a repeated study of the component composition of the body was carried out and the BMI index was calculated. The level of fat mass in these patients decreased to 29.06±3.46 % (against 33.9±5.08 % before treatment, p=0.04), the level of muscle mass increased to 32.5± 4.83 kg (against 30.44±4.66 kg before treatment), liquid – up to 50.24±1.69 % (against 47.2±2.73 % before treatment, p=0.01).
We also established a negative correlation between muscle mass indicators and BMI, weight, НOMA index (R=-0,54, р=0.002; R=-0.61, р=0.015; R=-0.68, р=0.0001), which makes it possible to confirm the role of the studied nutraceuticals on increasing muscle mass, weight correction and IR in these patients.
References
Amadou A, Ferrari P, Muwonge R, Moskal A, Biessy C, Romieu I, & Hainaut P. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: a systematic review and dose-response meta-analysis. Obesity reviews. 2013; 14(8): 665-678. DOI: https://doi.org/10.1111/obr.12028
Finkelstein EA, Khavjou OA, ThompsonH, Trogdon JG, PanL, Sherry B, & Dietz W. Obesity and severe obesity forecasts through 2030. American journal of preventive medicine. 2012; 42(6): 563-570. DOI: https://doi.org/10.1016/j.amepre.2011.10.026
Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomedicine & Pharmacotherapy. 2021; 137: 111315. DOI: https://doi.org/10.1016/j.biopha.2021.111315
Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Current opinion in lipidology. 2010; 21(1): 38-43. DOI: https://doi.org/10.1097/MOL.0b013e3283346ccc
Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obesity facts. 2017; 10(3): 207-215. DOI: https://doi.org/10.1159/000471488
Pi-Sunyer X. The medical risks of obesity. Postgraduate medicine. 2009; 121(6): 21-33. DOI: https://doi.org/10.3810/pgm.2009.11.2074
Tomiyama AJ. Stress and obesity. Annual review of psychology. 2019; 70(1): 703-718. DOI: https://doi.org/10.1146/annurev-psych-010418-102936
